Evidence map›Paper›PMID 30515156›Full record

ArticleFrontiers in immunology2018

Phosphatase of Regenerating Liver-1 (PRL-1) Regulates Actin Dynamics During Immunological Synapse Assembly and T Cell Effector Function.

Patricia Castro-Sánchez, Rocío Ramirez-Munoz, Noa B Martín-Cófreces, Oscar Aguilar-Sopeña, Sergio Alegre-Gomez, Sara Hernández-Pérez, Raquel Reyes, Qi Zeng, Carlos Cabañas, Francisco Sánchez-Madrid and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Targeting PRL phosphatases in hematological malignancies.Expert opinion on therapeutic targets · 2024
    Review
  2. Review
  3. Article
  4. β2 Integrins-Multi-Functional Leukocyte Receptors in Health and Disease.International journal of molecular sciences · 2020
    Review
  5. Article
  6. Regulation of CD4Frontiers in immunology · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Patricia Castro-SánchezDepartment of Immunology, School of Medicine, Universidad Complutense de Madrid, Madrid, Spain.
Rocío Ramirez-MunozDepartment of Immunology, School of Medicine, Universidad Complutense de Madrid, Madrid, Spain.
Noa B Martín-CófrecesServicio de Inmunología. Hospital Universitario de la Princesa, Universidad Autónoma de Madrid, Instituto de Investigación Sanitaria Princesa (IP), Madrid, Spain.
Oscar Aguilar-SopeñaDepartment of Immunology, School of Medicine, Universidad Complutense de Madrid, Madrid, Spain.
Sergio Alegre-GomezDepartment of Immunology, School of Medicine, Universidad Complutense de Madrid, Madrid, Spain.
Sara Hernández-PérezDepartment of Immunology, School of Medicine, Universidad Complutense de Madrid, Madrid, Spain.
Raquel ReyesDepartment of Cell Biology and Immunology, Center for Molecular Biology Severo Ochoa (CBM-SO), Mayor Council of Scientific Research (CSIC), Madrid, Spain.
Qi ZengInstitute of Molecular and Cell Biology, Agency for Science, Technology and Research (ASTAR), Singapore, Singapore.
Carlos CabañasDepartment of Immunology, School of Medicine, Universidad Complutense de Madrid, Madrid, Spain.
Francisco Sánchez-MadridServicio de Inmunología. Hospital Universitario de la Princesa, Universidad Autónoma de Madrid, Instituto de Investigación Sanitaria Princesa (IP), Madrid, Spain.
Pedro Roda-NavarroDepartment of Immunology, School of Medicine, Universidad Complutense de Madrid, Madrid, Spain.
Research Institute Hospital 12 de Octubre · ESUniversidad Complutense de Madrid · ESCentro de Biología Molecular Severo Ochoa · ESCentro de Investigación en Red en Enfermedades Cardiovasculares · ESAgency for Science, Technology and Research · SG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The regulatory role of most dual specific phosphatases during T cell activation remains unknown. Here, we have studied the expression and function of phosphatases of regenerating liver (PRLs: PRL-1, PRL-2, and PRL-3) during T cell activation, as well as, the dynamic delivery of PRL-1 to the Immunological Synapse (IS). We found that T cell activation downregulates the expression of PRL-2, resulting in an increased PRL-1/PRL-2 ratio. PRL-1 redistributed at the IS in two stages: Initially, it was transiently accumulated at scanning membranes enriched in CD3 and actin, and at later times, it was delivered at the contact site from pericentriolar, CD3ζ-containing, vesicles. Once at the established IS, PRL-1 distributed to LFA-1 and CD3ε sites. Remarkably, PRL-1 was found to regulate actin dynamics during IS assembly and the secretion of IL-2. Moreover, pharmacological inhibition of the catalytic activity of the three PRLs reduced the secretion of IL-2. These results provide evidence indicating a regulatory role of PRL-1 during IS assembly and highlight the involvement of PRLs in immune responses by mature T cells.

Indexed as

Lymphocyte ActivationActinsCD3 ComplexCell Cycle ProteinsFemaleHumansImmunological SynapsesInterleukin-2Lymphocyte Function-Associated Antigen-1MaleMembrane ProteinsProtein Tyrosine PhosphatasesT-LymphocytesActinsCD3 ComplexCD3E protein, humanCell Cycle ProteinsIL2 protein, humanInterleukin-2Lymphocyte Function-Associated Antigen-1Membrane ProteinsProtein Tyrosine PhosphatasesPTP4A1 protein, humanactin cytoskeletonIL-2immunological synapsephosphatases of regenerating liverT cell immune response

Identifiers

PMID30515156
PMCPMC6255827
OpenAlexW2901113905

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.